

# **Magnolia Market Access:**

### **Meet Your Presenters**



Beni Turner

Director,

Real World Clinical Insights



Martine Etschmaier
Senior Director,
Global Market Access & Value Insights



Pamela Landsman-Blumberg
Senior Vice President,
Real World Evidence & HEOR Strategy




# **Objectives**



- Of Defining Unstructured Data
- **02** Unstructured Data Sources
- **03** Curation Considerations
- **04** Practical Applications
- Future Trends & Innovation Opportunities






# The Big Data Era: Unraveling the Vastness of Our Digital Universe






# Mapping the Data Cosmos: From Sources to Collection to Insight



#### **Unstructured Data**

- Information that doesn't fit neatly into a predefined data model or schema
- · Has no inherent organization and requires some level of curation for analysis and insight generation





# **Navigating Unstructured Data Sources**

**Charting the Course for Market Access Strategy** 

Healthcare Provider Notes
Pathology Reports
Imaging Reports
Claims Data
Clinical Trial Results

Conference Presentations

Scientific Literature

Clinical Guidelines

**Expert Opinions** 



Patents
Regulatory
Updates
Policy Papers
Industry News
Social Media
Interviews
Online Forums



## **Unstructured Data to Inform Market Access Strategy – Selected Example Sources**

**Choosing the Right Methodology for Primary Market Research to Gather Insights From Key Stakeholders** 



Primary market research provides manufacturers with proof of assumptions, key unknowns in the market, actionable next steps, etc., and can service as a support function for other market access tools



# **Understanding Data Curation**

The process of providing shape to shapeless data





#### **Important Curation Considerations**

- Based on data use and audience, may need to consider:
  - Annotation
  - Linking
  - Compliance
  - Monitoring & Updating



# **Shaping Chaos: Varying Levels of Structure in Unstructured Data Curation**

CHAOS

**ORDER** 

The level of data structure provided through curation efforts exists along a continuum



# **Shaping Chaos:** Varying Levels of Structure in Unstructured Data Curation




**Loosely** structured curation can include:

- Thematic Mapping
- Concept Mapping
- Sentiment Analysis



# **Shaping Chaos:** Varying Levels of Structure in Unstructured Data Curation



## **Highly** structured curation can include:


- Coding Qualitative Data
- Systematic Literature Review
- Clinical Chart Review or Abstraction



# **Curation Concerns Begin at Project Ideation**

#### **DATA RELIABILITY**

Curated data feeds should be continuously tested for reliability and accuracy against source data




# INTERPRETING MISSINGNESS

Lack of or missing data does not necessarily indicate a no

# ADDRESSING BIAS

Design of curation plans should be done with an eye for potential sources of bias



# CROSS FUNCTIONAL COLLABORATION

Development of data capture forms and collection system logic should be performed with representative input across the project team

# **Curating Unstructured Data Utilizing AI, NLP, & LLMs**

**Ensuring Accuracy & Quality in Al Curated Data** 

1)



#### **SOURCING DATA**

Data sources should be diverse

Reduce risk of bias and false positives, data sources should be relevant and specific to the project, heterogenous, and representative of diverse populations and/or opinions

2



#### **TRAINING**

Algorithms require training to ensure *true positive* results

Critical to ensure that algorithms or models used are consistently and specifically trained and validated on data of interest for the analysis

3



#### **REVIEW**

*Human monitoring* of algorithms is necessary


Comply with regulatory standards through the use of regular, streamlined human review of algorithm curated data



# **Data Integrity:** The Essential Role of Retaining Source Links & Audit Trails
















How Can Unstructured Data Solve for Present Day Challenges In Market Access



#### **Real-World Treatment Performance**

#### **Enhancing Traditional Structured Real-World Evidence Insights**



#### Challenge

- Market access decisions
   often require evidence of a
   treatment's effectiveness in
   the real world, beyond highly
   controlled clinical trial data
- Real-world treatment practices may differ from guidelines



#### **Unstructured Data**

- Healthcare Provider Notes
- Pathology Reports
- Imaging Reports
- Claims Data











- Demonstrate value
- Support & enhance submission value
- Competitor evaluation
- Enhance pricing & positioning strategies



## **The Payer Perspective**

**Strengthen Value Propositions, Evidence Plans & Coding Strategies** 



#### Challenge

- Smaller sample sizes limit ability to extrapolate to each payer segment
- Value of product to stakeholders is unclear
- Payers have data needs that differ from data garnered for regulatory review
- Inadequate coding can make patient and treatment identification difficult



#### **Unstructured Data**

- Clinical Guidelines
- Expert Opinions
- Interviews
- Policy Papers
- Industry News





- Maximize access
- Gain insights for data generation activities
- Uncover barriers
- Validate economic model assumptions
- Confirming price and rebate strategies
- Support creation or affirmation of codes



## **Competitive Intelligence**

Leveraging Unstructured Data to Enhance Competitive Market Intelligence



#### Challenge

- Staying updated on competitors' market strategies and product performance is critical
- Understanding market landscape requires constant review of unstructured data



#### **Unstructured Data**

- Conference Presentations
- Patents
- Clinical Trial Results
- News Articles











- Gain intelligence to assist with product positioning
- Identify emerging trends
- Proactive pipeline customized to unmet needs



# **Providing Context: Size & Content of the EHR**

In the US, hospitals alone generate an average of 838,440 terabytes of patient medical data per day



# **Providing Context: Size & Content of the EHR**



12,000 times
the size of the
entire Netflix
content library

Magno





# If the EHR is an Iceberg...



Structured Data is what's visible above the water <20%

**Unstructured Data** is below the water's surface >80%

# If the EHR is an Iceberg: What We Can See Above Water

- **Demographics**: Sex, Age, Ethnicity, etc.
- Diagnosis and Billing Codes: ICD-CP ICD-PM, CPT, HPCS, LOINC
- Numerical Values: Height, Weight, BP, etc.
- Categorical Values: Blood Type, Disease stages of diagnosis, etc.
- Medications
- DE&I

# If the EHR is an Iceberg: What is Below the Surface?



- Signs & Symptoms
- Provider Notes, Results, & Reports (Clinical, Pathology, Operative, Imaging, Discharge Summaries, etc.)
- Procedure Details
- Problem Lists
- Lab Reports
- Genomics Reports
- OTC Medications
- Tumor Size & Characteristics
- Minimum Residual Disease
- Lines of Therapy
- Reasons for Medication Discontinuation
- Disease Severity Measures
- Patient Reported Outcomes
- Social History & Nuanced, Nonclinical Social Needs
- Patient Generated Data (wearable, DTx, etc.)

# If the EHR is an Iceberg: What is Below the Surface?

Unstructured Data may be at different depths

**Curation Difficulty Increases**with Data Depth

# If the EHR is an Iceberg: Changes in Water Levels



- Signs & Symptoms
- Date of Death
- Cause of Death
- Lab Results
- Behavioral Risk Factors

- Disease Assessment Scales
- Progression-Free Survival
- Performance Scores
- Histology & Genomics

## **Real-World Patient Experience**

**Demystifying the Patient Experience Outside Clinical Trials** 



#### Challenge

- Siloed data streams
- Lack of information surrounding patient sentiment, experience, and concerns in structured data



#### **Unstructured Data Sources**

- Healthcare Provider Notes
- Social Media
- Online Forums
- Pathology Reports
- Imaging Reports











- Reveal important patient details
- Identify emerging trends
- Increased strategy specificity
- Improve access and support



## The Regulatory Landscape

Tracking Regulatory Updates, Optimizing HTA Submissions, & Enhancing Clinical Trials with RWD



#### Challenge

- Constantly evolving guidelines and requirements for regulatory considerations
- Timely information critical to compliance
- Inherent clinical trial enrollment challenges, including lack of diversity, pharmaceutical companies require integration of novel data generation methods



#### **Unstructured Data**

- Scientific Literature
- Clinical Guidelines
- Expert Opinions
- Regulatory Updates
- Policy Papers
- Industry News





- Proactive & timely strategy adjustments
- Enhance cost evidence
- Ensure continuous compliance
- Maintain competitive advantage





# The Value: Incorporating Unstructured Data in Market Access Strategy

Optimize Pricing & Reimbursement
Strategy

Tailor Stakeholder Engagement Influence
Regulatory & Policy
Adaptation

Improve Resource Allocation









Patient-Centered Strategies



Incorporate
Predictive Analytics
& Forecasting



Crisis & Reputation Management







Opportunities for Innovation in Unstructured Data Curation



# **Future Trends & Innovation Opportunities**

Increased Need for Interoperability Focus

01

Expanding Al-Driven Curation

Novel Approaches to Ethical Considerations

03



Data Quality & Management

Crowdsourcing & Collaborative Curation

Shifting to Real-Time Curation

O4 Supercharging the Audit Trail





# Thank you!

Pamela Landsman-Blumberg

SVP, Real-World Evidence & HEOR Strategy

pblumberg@magnoliamarketaccess.com

#### **Martine Etschmaier**

Senior Director, Global Market Access & Value Insights <a href="magnoliamarketaccess.com"><u>metschmaier@magnoliamarketaccess.com</u></a>

Beni Turner
Director, Real-World Clinical Insights
bturner@magnoliamarketaccess.com

